Symptomtext
No symptoms or adverse effects from administration of these vaccines; 4-year-old patient received PROQUAD and VARIVAX concomitantly; This spontaneous report has been received from a medical assistant referring a 4-years-old patient of unknown gender. The patient's pertinent medical history, drug allergies, previously drug reactions, concurrent conditions and concomitant medication were not reported. On 03-AUG-2022, the patient received a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant human albumin (rHA) (PROQUAD) subcutaneous injection, at the dose of 0.5 milliliters (ml), once for prophylaxis, (lot number U031561 had been verified to be a valid number, expiration date was reported and established as 06-APR-2023) (strength, route of administration and anatomical location were not provided). And with varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, at the dose of 0.5 ml for prophylaxis, (lot number U015687 had been verified to be a valid number, expiration date was reported and establised as 18-MAY-2023) (strength, route of administration and anatomical location were not provided) (drug use for unapproved schedule). Both reconstituted with sterile diluent solution for injection, at a dose of 0.7 ml (lot number T020662 had been verified to be a valid number, expiration date was reported and established as 30-DEC-2022). Patient had no symptoms or adverse effects from administration of these vaccines.